Unlocking breakthroughs: Japan-Luxembourg collaboration unveils key discoveries for diagnosing neurodegenerative diseases
02 June 2023
Better diagnosis of neurodegenerative diseases
Japanese and Research Luxembourg researchers have joined forces to make a major discovery: detecting markers of neurodegenerative diseases from a simple blood test.
An international team consisting of researchers from Japan and Luxembourg show for the first time that pathological forms of the alpha-synuclein protein present in the blood of patients can be used for the diagnosis of Parkinson’s disease and its differentiation from several other neurodegenerative motor disorders.
Their ground-breaking results, recently published in Nature Medicine, constitute a major step towards developing better diagnostics based on a simple blood test.
Searching for the α-synuclein protein
Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy compose a group of neurodegenerative disorders called synucleinopathies. They are caused by the abnormal aggregation of a protein called α-synuclein. These aggregates progressively appear in the brain of patients causing neuronal cell death and leading to different neurological symptoms, from tremor to dementia, depending on the area of the brain affected. Currently, there is no curative treatment for this group of diseases and diagnosis can be a lengthy process, involving clinical examinations and medical imaging. Furthermore, differentiation between these disorders is a challenge in the early stages.
As previous studies have revealed that α-synuclein accumulates not only in the brain but also in peripheral nerves, researchers from Juntendo University, the RIKEN Centre for Brain Science and Nagasaki University hypothesised that so-called α-synuclein seeds could also be found in the blood of patients. These pathological forms of the protein that can induce the misfolding and aggregation of normal α-synuclein molecules would circulate through the vascular system and contribute to the progression of the disease.
We thought a blood-borne biomarker may reflect the pathological spread of the disease. This is why we developed a novel method to detect very small amounts of α-synuclein seeds in serum and then conducted a large-scale screening of patients with different synucleinopathies.
We thought a blood-borne biomarker may reflect the pathological spread of the disease. This is why we developed a novel method to detect very small amounts of α-synuclein seeds in serum and then conducted a large-scale screening of patients with different synucleinopathies.Prof. Nobutaka Hattori, at the Department of Neurology of Juntendo University and current head of the Neurodegenerative Disorders Collaboration Laboratory at RIKEN Centre for Brain Science
The method called IP/RT-QuIC relies on immunoprecipitation (IP) to concentrate the misfolded proteins in the patients’ serums and on real-time quaking-induced conversion (RT-QuIC) to amplify these α-synuclein seeds.
Luxembourg’s remarkable Parkinson’s disease database
The Japanese researchers teamed up with scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, the Luxembourg Institute of Health (LIH) and the Laboratoire National de Santé (LNS) to benefit from the unique longitudinal clinical and neuropathological database established during the past decade in Luxembourg, as part of the National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD).
“We have been following large groups of people diagnosed with Parkinson’s disease and other forms of parkinsonism annually for up to nine years, meaning that we have traced their clinical progression and collected biological samples such as blood, cerebrospinal fluid and brain tissue from autopsies,” details Prof. Rejko Krüger, director of Transversal Translational Medicine at the LIH and head of the Translational Neuroscience group at the LCSB. “Our specific study design allows for comparison between different synucleinopathies and helps to differentiate them from other neurodegenerative diseases.” Prof. Michel Mittelbronn, head of the Luxembourg National Centre of Pathology, adds: “We have also established the Luxembourg Brain Bank which gives us access to brains donated by study participants for post-mortem analyses. It provides complementary neuropathological diagnostics, the gold standard for diagnosing neurodegenerative disorders, which can be used to validate clinical findings.”
A simple blood test to detect neurodegenerative disorders
The collaboration proved successful: the IP/RT-QuIC method detected α-synuclein seeds in the serum of 95% of patients with synucleinopathies. In addition, it also showed that the structure of these seeds shows specific patterns that differ between diseases. Interestingly, the aggregation and propagation of the seeds replicated these patterns in in vitro and in vivo models of Parkinson’s disease.
Not only have we succeeded in detecting α-synuclein seeds in the serum of patients with Parkinson’s disease and other disorders. Our team has also discovered, for the first time, that these α-synuclein seeds have structures and properties characteristic of each disease, suggesting that they shape the pathology of each synucleinopathy.Prof. Hattori
In conclusion, α-synuclein seeds are useful markers for the diagnosis of Parkinson’s disease and its differentiation from several other neurodegenerative disorders. These ground-breaking results will help to establish a simple diagnostic test based on the presence and specific shape of α-synuclein seeds in serum: a game-changer when it comes to the diagnosis of synucleinopathies.
Being able to diagnose Parkinson’s disease with a simple blood test will be a major progress as diagnosis is currently largely based on clinical examination by a neurologist. We are very proud to contribute to this pioneering research collaboration with the Luxembourg Parkinson’s Study. It illustrates the importance of deep-phenotyped cohorts – for which comprehensive data have been collected – to address major unmet needs of people with Parkinson’s disease.Prof. Krüger
Reference : Ayami Okuzumi, Taku Hatano, Gen Matsumoto, Shuko Nojiri, Shin-ich Ueno, Yoko Imamichi1, Haruka Kimura, Soichiro Kakuta, Akihide Kondo, Takeshi Fukuhara, Yuanzhe Li, Manabu Funayama, Shinji Saiki, Daisuke Taniguchi, Taiji Tsunemi, Deborah McIntyre, Jean-Jacques Gérardy, Michel Mittelbronn, Rejko Krüger, Yasuo Uchiyama, Nobuyuki Nukina & Nobutaka Hattori, Propagative α-synuclein seeds in the serum of patients with synucleinopathies, Nature Medicine, May 2023.
10 selected Research Luxembourg results – August 2023Are our European rivers in good health? Luxembourg Institute of Science and Technology (LIST) Over the past few decades, life…
10 selected Research Luxembourg results – July 2023An antibody to tackle skin cancer? Laboratoire National de Santé (LNS), Luxembourg Centre for Systems Biomedicine (LCSB), Luxembourg Institute of…
A new breakthrough in cancer treatmentAn international team of researchers, including Prof. Michel Mittelbronn, Head of the National Centre of Pathology at the Laboratoire Nationale…
SciLux podcast – Catherine Sedrani, microbiologistCould we find another link between what we eat and the diseases we develop? A Gut-On-A-Chip model Dr Catherine Sedrani…
10 selected Research Luxembourg results – June 2023When artificial intelligence explores space Interdisciplinary Centre for Security, Reliability and Trust (SnT) – University of Luxembourg AI is increasingly…
Cutting-edge research in Luxembourg: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing GenesResearchers from the Luxembourg Institute of Health reveal the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation…
10 selected Research Luxembourg results – May 2023A blood test for effective diagnosis of Parkinson’s disease NCER-PD (LCSB, LIH, IBBL, CHL, LNS) Is it now possible to…
10 selected Research Luxembourg results – April 2023Can artificial intelligence guide our artistic choices? University of Luxembourg The answer obviously depends on our expectations! AI could, for…
Unlocking breakthroughs: Japan-Luxembourg collaboration unveils key discoveries for diagnosing neurodegenerative diseasesAn international team consisting of researchers from Japan and Luxembourg show for the first time that pathological forms of the…
Prof. Tkatchenko receives an ERC grant for drug development with AIThe physicist Prof. Alexandre Tkatchenko of the University of Luxembourg, has received a “Proof of Concept” Grant from the European…